Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 7/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.41 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28588272 | 1.00 | PIN1 (0.51) | PIN1DRD2USP30PARP1SMYD3 | |
| SCHEMBL28588273 | 1.00 | PIN1 (0.51) | PIN1DRD2USP30PARP1SMYD3 | |
| SCHEMBL30180476 | 0.82 | DRD2 (0.51) | DRD2USP30PARP1SMYD3 | |
| SCHEMBL28578331 | 0.82 | DRD2 (0.51) | DRD2USP30PARP1SMYD3 | |
| SCHEMBL28578333 | 0.82 | DRD2 (0.51) | DRD2USP30PARP1SMYD3 | |
| SCHEMBL30180683 | 0.77 | KDM1A (0.55) | DRD2IRAK4 | |
| SCHEMBL28588619 | 0.77 | KDM1A (0.55) | DRD2IRAK4 | |
| SCHEMBL28588616 | 0.77 | KDM1A (0.55) | DRD2IRAK4 | |
| SCHEMBL28588643 | 0.76 | DRD2 (0.45) | DRD2IRAK4AAK1 | |
| SCHEMBL28588642 | 0.76 | DRD2 (0.45) | DRD2IRAK4AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860636-B1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | DISC MEDICINE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | MMP7, MATR3, SPINT2 | PIN1 402/4885DRD2 4828/4885USP30 2653/4885 |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | PIN1 402/4885DRD2 4828/4885USP30 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.